Skip to Content

Loretta J. Nastoupil

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Lymphoma Outcomes Database, UT MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2007 University of Texas Southwestern Medical Center, Dallas, TX, MD, Medicine
2003 Texas Tech University Health Science Center, Lubbock, TX, BS, Clinical Laboratory Science

Postgraduate Training

7/2010-6/2013 Clinical Fellowship, Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Dr. Ruth O'Regan
6/2007-6/2010 Clinical Internship, Medicine, Washington University School of Medicine, St Louis, MO, Dr. Melvin Blanchard

Board Certifications

2010 American Board of Internal Medicine


Other Appointments/Responsibilities

Member, ASCO Health Disparities Committee, Alexandria, VA, 6/2015-present
Liaison, ASCO Clinical Practice Guidelines Committee, Alexandria, VA, 6/2015-present

Institutional Committee Activities

Fellowship Committee, Member, MDACC Hematology/Medical Oncology, 6/2015-present

Honors and Awards

2013-2015 ASH Scholar Award
2013 Leukemia & Lymphoma Society Special Fellow in Clinical Research
2012 Chief Fellow, Winship Cancer Institute/Emory University School of Medicine
2012 Elkin Cancer Research Fellowship Award, 2012, Emory University
2011 ASH Abstract Acheivement Award, ASH
2008 Mentors in Medicine, Washington University, St Louis MO, 2008
2003 Summa Cum Laude, Texas Tech University of Health Sciences Center

Professional Memberships

American Society of Clinical Oncology (ASCO), Alexandria, VA
Member, 2010-present
American Society of Hematology (ASH), Washington, DC
Member, 2010-present
Clinical Practice Guidelines Committee
Member, 2015-present
Health Disparatities Committee
Member, 2015-present
Texas Medical Association, Austin, TX
Member, 2013-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol 2(8):1065-9, 8/1/2016. e-Pub 5/26/2016. PMID: 27227654.
2. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol. e-Pub 7/5/2016. PMID: 27378601.
3. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol. e-Pub 7/22/2016. PMID: 27448187.
4. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol 27(7):1317-23, 7/2016. e-Pub 4/18/2016. PMID: 27091808.
5. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. e-Pub 6/28/2016. PMID: 27351173.
6. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol 27(5):895-901, 5/2016. e-Pub 1/22/2016. PMID: 26802151.
7. Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, Bollard C, Ansell S, Curran M, Wilson WH, O'Brien S, Grant C, Little R, Zenz T, Nastoupil LJ, Dunleavy K. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica 101(5):531-40, 5/2016. PMID: 27132279.
8. Chen Q, Ayer T, Nastoupil LJ, Koff JL, Staton AD, Chhatwal J, Flowers CR. Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma. Leuk Lymphoma 57(4):1-26, 4/2016. e-Pub 12/15/2015. PMID: 26415108.
9. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk 16(3):122-8, 3/2016. e-Pub 12/22/2015. PMID: 26795083.
10. Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Zhou X, Taylor M, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era. Br J Haematol 172(5):724-34, 3/2016. e-Pub 1/5/2016. PMID: 26729445.
11. Cheah CY, Nastoupil LJ, McLaughlin P, Fanale MA, Neelapu SS, Fayad LE, Hagemeister FB, Fowler NH. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. Br J Haematol. e-Pub 12/18/2015. PMID: 26683805.
12. Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, Weisenburger DD, Liu J, Morgan EA, Kanagal-Shamanna R, Parkash V, Ning J, Sohani AR, Ferry JA, Mehta-Shah N, Dogan A, Liu H, Thormann N, DiNapoli A, Lade S, Piccolini J, Reyes R, Williams T, McCarthy CM, Hanson SE, Nastoupil LJ, Gaur R, Oki Y, Young KH, Miranda RN. Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. J Clin Oncol. e-Pub 11/2015. PMID: 26628470.
13. Cohen JB, Switchenko JM, Koff JL, Sinha R, Kaufman JL, Khoury HJ, Bumpers N, Colbert A, Hutchison-Rzepka A, Nastoupil LJ, Heffner LT, Langston AA, Lechowicz MJ, Lonial S, Flowers CR. A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. Br J Haematol. e-Pub 8/2015. PMID: 26248505.
14. Fowler NH, Nastoupil LJ, Hagemeister FB, Neelapu SS, Fayad LE, LeBlanc D, Samaniego F, Cheah CY. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. Haematologica. e-Pub 8/2015. PMID: 26250576.
15. Flowers CR, Nastoupil LJ. Identifying racial differences in nodular lymphocyte-predominant Hodgkin lymphoma. Cancer. e-Pub 7/2015. PMID: 26149195.
16. Nastoupil LJ, Neelapu SS. Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system. Curr Oncol Rep 17(7):456, 7/2015. PMID: 25986722.
17. Koff JL, Chihara D, Phan A, Nastoupil LJ, Williams JN, Flowers CR. To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes. Curr Hematol Malig Rep. e-Pub 6/2015. PMID: 26104907.
18. Cheah CY, Nastoupil LJ, Neelapu SS, Forbes SG, Oki Y, Fowler NH. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood 125(21):3357-9, 5/2015. PMID: 25999447.
19. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys 92(1):175-182, 5/2015. PMID: 25863764.
20. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment by (18)Fluorodeoxyglucose Positron Emission Tomography. Int J Radiat Oncol Biol Phys 92(1):113-121, 5/2015. PMID: 25863759.
21. Chihara D, Nastoupil LJ, Williams JN, Lee P, Koff JL, Flowers CR. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. Expert Rev Anticancer Ther. e-Pub 4/2015. PMID: 25864967.
22. Chen Q, Ayer T, Nastoupil LJ, Rose AC, Flowers CR. Comparing the Cost-Effectiveness of Rituximab Maintenance and Radioimmunotherapy Consolidation versus Observation Following First-Line Therapy in Patients with Follicular Lymphoma. Value Health 18(2):189-97, 3/2015. PMID: 25773554.
23. Oki Y, Younes A, Knickerbocker J, Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N, Kwak L, Westin J. Experience with HSP90 inhibitor AUY922 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Haematologica. e-Pub 3/2015. PMID: 25820332.
24. Williams JN, Rai A, Lipscomb J, Koff JL, Nastoupil LJ, Flowers CR. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. Cancer. e-Pub 2/2015. PMID: 25675909.
25. Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Taylor M, Friedberg JW, Koff JL, Link BK, Cerhan JR, Dawson KL, Flowers CR. Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. Leuk Lymphoma 55(5). e-Pub 11/2014. PMID: 25263322.
26. Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol 25(11):2211-7, 11/2014. e-Pub 9/2014. PMID: 25193992.
27. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15(12):1311-8, 11/2014. e-Pub 10/2014. PMID: 25439689.
28. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 167(2):177-84, 10/2014. e-Pub 7/2014. PMID: 25039868.
29. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 9/2014. e-Pub 6/2014. PMID: 24943107.
30. Nastoupil LJ. Routine use of maintenance therapy in follicular lymphoma: the strategy is effective, raising the question, 'what is the most important measure of success in the current era?'. Oncology (Williston Park) 28(9), 9/2014. PMID: 25224478.
31. Nastoupil LJ, Shenoy PJ, Ambinder A, Koff JL, Nooka AK, Waller EK, Langston A, Seward M, Kaufman JL, Bernal-Mizrachi L, King N, Lechowicz MJ, Lonial S, Sinha R, Flowers CR. Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. Leuk Lymphoma. e-Pub 7/2014. PMID: 24828864.
32. Read JA, Koff JL, Nastoupil LJ, Williams JN, Cohen JB, Flowers CR. Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms. Clin Lymphoma Myeloma Leuk 14(6). e-Pub 6/2014. PMID: 25052052.
33. Flowers CR, Nastoupil LJ. Socioeconomic disparities in lymphoma. Blood 123(23):3530-1, 6/2014. PMCID: PMC4047493.
34. Nastoupil LJ, Sinha R, Byrtek M, Zhou X, Taylor MD, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer 120(12):1830-7, 6/2014. e-Pub 3/2014. PMID: 24668580.
35. Han X, Jemal A, Flowers CR, Sineshaw H, Nastoupil LJ, Ward E. Insurance status is related to diffuse large B-cell lymphoma survival. Cancer 120(8):1220-7, 4/2014. e-Pub 1/2014. PMID: 24474436.
36. Nastoupil LJ, Koff JL, Flowers CR. Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies. Oncology (Williston Park) 27 Suppl 2:8-12, 10/2013. PMID: 25374999.
37. Bulka C, Nastoupil LJ, McClellan W, Ambinder A, Phillips A, Ward K, Bayakly AR, Switchenko JM, Waller L, Flowers CR. Residence proximity to benzene release sites is associated with increased incidence of non-Hodgkin lymphoma. Cancer 119(18):3309-17, 9/2013. e-Pub 7/2013. PMID: 23896932.
38. Nastoupil LJ, Sinha R, Flowers CR. The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy. Expert Rev Anticancer Ther 13(9):1089-108, 9/2013. e-Pub 8/2013. PMID: 23919536.
39. Shi Z, Das S, Okwan-Duodu D, Esiashvili N, Flowers C, Chen Z, Wang X, Jiang K, Nastoupil LJ, Khan MK. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Int J Radiat Oncol Biol Phys 86(3):569-77, 7/2013. e-Pub 3/2013. PMID: 23540349.
40. Ambinder AJ, Shenoy PJ, Nastoupil LJ, Flowers CR. Using primary site as a predictor of survival in mantle cell lymphoma. Cancer 119(8):1570-7, 4/2013. e-Pub 1/2013. PMID: 23341329.
41. Rose AC, Shenoy PJ, Garrett G, Seward M, Kucuk RA, Doksansky H, Nastoupil LJ, Flowers CR. A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma. Clin Lymphoma Myeloma Leuk 12(6):393-9, 12/2012. PMID: 23158095.
42. Nastoupil LJ, Flowers CR. Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice. Community Oncol 9(12):S85-S92, 12/2012. PMCID: PMC3541037.
43. Nastoupil L, Sinha R, Hirschey A, Flowers CR. Considerations in the initial management of follicular lymphoma. Community Oncol 9(11):S53-S60, 11/2012. PMCID: PMC3610920.
44. Chen Q, Ayer T, Nastoupil LJ, Seward M, Zhang H, Sinha R, Flowers CR. Initial management strategies for follicular lymphoma. Int J Hematol Oncol 1(1):35-45, 10/2012. PMCID: PMC3587762.
45. Flowers CR, Fedewa SA, Chen AY, Nastoupil LJ, Lipscomb J, Brawley OW, Ward EM. Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States. Cancer Epidemiol Biomarkers Prev 21(9):1520-30, 9/2012. PMID: 22771484.
46. Nastoupil LJ, Rose AC, Flowers CR. Diffuse large B-cell lymphoma: current treatment approaches. Oncology (Williston Park) 26(5):488-95, 5/2012. PMID: 22730604.
47. Nastoupil LJ, Sinha R, Flowers CR. Management Strategies for Elderly Patients with Diffuse Large B-Cell Lymphoma. Eur Oncol Haematol 8(2):123-126, 5/2012. PMCID: PMC3690666.
48. Sinha R, Nastoupil L, Flowers CR. Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future. Blood Lymphat Cancer 2012(2):87-98, 4/2012. PMCID: PMC3606548.
49. Flowers CR, Nastoupil LJ, Bernal-Mizrachi L, Rose AC, Sinha R. New Challenges in the Management of Diffuse Large B-Cell Lymphoma. Treat Strategies Hematol 2(1):68-73, 1/2012. PMCID: PMC3690658.
50. Ambinder AJ, Shenoy PJ, Malik N, Maggioncalda A, Nastoupil LJ, Flowers CR. Exploring risk factors for follicular lymphoma. Adv Hematol 2012:626035, 2012. e-Pub 9/2012. PMCID: PMC3458409.
51. Shenoy PJ, Malik N, Sinha R, Nooka A, Nastoupil LJ, Smith M, Flowers CR. Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States. Clin Lymphoma Myeloma Leuk 11(6):498-506, 12/2011. PMID: 21889433.


1. de Vos S, Swinnen L, Kazloff M, Wang D, Reid E, Nastoupil L, Fowler N, Cordero J, D'Amico D, Diehl S, Dunbar M, Zhu M, Wong S, Enschede S, Chien D, Humerickhouse R, Flowers C. A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma. Blood (2015 ASH Annual Meeting) 126(23), 12/2015.
2. Fowler N, Pinto R, Cheah C, Nelapu S, Turturro F, Hagemeister F, Romaguera J, Fanale M, Fayad L, Forbes S, Khan J, Feng L, Samaniego F, Nastoupil L. A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma. Blood (2015 ASH Annual Meeting) 126(123), 12/2015.
3. Lee MJ, Switchenko J, thomas J, Koff J, Nastoupil L, Lachowicz M, Langstrom A, Flowers C, Choen J. Complex Karyotype in Mantle Cell Lymphoma (MCL) is Associated with Inferior Progression-Free Survival in Patients (pts) Receiving R-Hypercvad Followed by Autologous Stem Cell Transplant. Blood (2015 ASH Annual Meeting) 126(23), 12/2015.
4. Chihara D, Oki Y, Westin J, Nastoupil L, Fayad L, Samaniego F, Wesson E, Roben C, Horowitz S, Feng L, Carg N, Ahmed S, Khouri I, Hosing C, Romaguera J, Fowler N, Fanale M. High Response Rate of Romidepsin in Combination with ICE(Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: Updates of Phase I Trial. Blood (2015 ASH Annual Meeting) 126(123), 12/2015.
5. Fowler N, Nastoupil L, de Vos S, Knapp M, Flinn I, Chen R, Advani R, Bhatia S, Martin P, Mena R, Suzuki S, Beaupre D, Neuenburg J, Palomba M. Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter Phase 2 Study. Blood (2015 ASH Annual Meeting) 126(123), 12/2015.
6. Khouri I, Sui D, Turturro F, Erwin W, Bassett R, Korbling M, Valverde R, Ahmed S, Alousi A, Anderlini P, Bashire Q, Cuirea S, Oran B, Olson A, Popat U, Patel K, Qazilbash M, Fanale M, Fayad L, Nastoupil L, Westin J, Culbis A, Medeiros J, Young K, Jessop A. In-Vivo Purgine with Rituximab (r) Followed by Z/BEAM vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials. Blood (2015 ASH Annual Meeting) 126(123), 12/2015.
7. Chihara D, Ahmed M, Oki Y, Westin J, Hagemeister F, Romaguera J, Fanale M, Lee JH, Turturro F, Samaniego F, Neelapu S, Rodriguez A, Fowler, N, Wang M, Fayad L, Davis RE, Nastoupil L. Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood (2015 ASH Annual Meeting) 126(123), 12/2015.
8. Ahmed M, Oki Y, Noorani M, Nastoupil L, Fayad L, Hagemeister F, Rodriguez A, Davis RE, Westin J. The Clnical Outcome of Newly Diagnosed Patients >60 Years of Age with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Standard or Liposomal Chemotherapies. Blood (2015 ASH Annual Meeting) 126(123), 12/2015.
9. Chihara D, Fanale M, Noorani M, Westin J, Nastoupil L, Hagemeister F, Fayad L, Romaguera J, Samaniego F, Turturro F, Le HJ, Neelapu S, Rodriguez A, Wang M, Fowler N, Miranda R, Hosing C, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma. Bood (2015 ASH Annual Meeting) 126(123), 12/2015.
10. Chihara D, Fanale M, Noorani M, Westin J, Nastoupil L, Hagemeister F, Fayad L, Romaguera J, Samaniego F, Turturro F, Lee HJ, Neelapu S, Rodriguez A, Wang M, Fowler N, Miranda R, Hosing C, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL. Blood (2015 ASH Annual Meeting) 126(23), 12/2015.
11. Lunning M, Vose J, Fowler N, Nastoupil L, Burger J, Wierda W, Schreeder M, Siddiqi T, Flowers C, Cohen J, Blumel S, Migues M, Cutter K, Pauli E, Handy R, Sportelli P, Miskin H, Weiss M, O'Brien S. Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results. Blood (2015 ASH Annual Meeting) 126(123), 12/2015.
12. Rai A, Nastoupil L, Williams J, Lipscomb J, Ward K, Howard DH, Flowers C. Determinants and Outcomes of the Use of Positron Emission Tomography (PET)-Staging in Newly Diagnosed Follicular Lymphoma (FL). Blood (ASH Annual Meeting 2014) 124(21), 12/2014.
13. Williams J, rai A, Lipscomb J, Koff JL, Nastoupil L, Flowers CR. Disease Characteristics, Patterns of Care, and Survival in Very Elderly Patients with Diffuse Large B-Cell Lymphoma. Blood (ASH Annual Meeting 2014) 124(21), 12/2014.
14. Nastoupil L, Han X, Jemal A, Ward E, Flowers DR. Insurance Status Impacts Survival in Follicular Lymphoma. Blood (ASH Annual Meeting 2014) 124(21), 12/2014.
15. Phansalkar K, Ahmed MA, Fowler N, Ma Long, Noorani M, Lee ST, Feng L, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez A, Samaniego F, Fanale M, Wang M, Oki Y, Turturro F, Westin J, Nastoupil L, Kwak L, David RE, Neelapu S. R-Bendamustine vs R-CHOP as Initial Treatment for Advanced Stage Low Grade Follicular Lymphoma: A Matched-Pair Analysis. Blood (ASH Annual Meeting 2014) 124(21), 12/2014.
16. Mohamed AA, Fowler N, Ma L, Noorani M, Phansalkar K, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez A, Samaniego F, Fanale M, Wan M, Oli Y, Turturro F, Westin J, Kwak L, Nastoupil L, Cheah C, Feng L, Rohren EM, David RE, Neelapu S. SUVmax on Pre-Treatment FDG PET Scan is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Therapy. Blood (ASH Annual Meeting 2014) 124(21), 12/2014.
17. Lunning MA, Vose JM, Schreeder MT, Fowler N, Nastoupil L, Siddiqu T, Blumel S, Paull EK, Cutter K, Tse W, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Viswanadha S, O'Brien S. Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3k Inhibitor, Demonstrates Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma. Blood (ASH Annual Meeting 2014) 124(21), 12/2014.

Book Chapters

1. Nastoupil L. Indolent Lymphoma. In: M.D. Anderson Manual of Medical Oncology, III, 2016.

Grant & Contract Support

Title: (1 U01 CA195568-01)
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 6/1/2015 - 5/31/2020
Title: Carniol-Rich Endowment
Funding Source: Carniol-Rich Endowment
Role: Principal Investigator
Duration: 6/1/2014 - 5/31/2015
Title: NIH Loan Repayment Award
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 10/1/2013 - 9/30/2015
Title: ASH Fellow Scholar Award
Funding Source: American Society of Hematology (ASH)
Role: Postdoctoral Fellow
Duration: 7/1/2013 - 6/30/2015
Title: Elkin Fellowship Award
Funding Source: Emory University
Role: Principal Investigator
Duration: 7/1/2012 - 6/30/2013

Last updated: 9/1/2016